GlassScriptPhysician profile
Jyoti S Pham
NPI 1093704181
$3,649.65
in general payments reported to CMS, 2019-2025
38 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $519 · 2021: $524 · 2022: $277 · 2023: $557 · 2024: $843 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $422.57 | 2019-2024 | Belbuca |
| Ipsen Biopharmaceuticals, INC | $410.96 | 2019-2025 | Dysport |
| Abbvie INC. | $306.76 | 2022-2025 | |
| Horizon Therapeutics Plc | $302.00 | 2019-2022 | |
| Microtransponder, INC. | $294.72 | 2024 | |
| Allergan, INC. | $264.30 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $227.40 | 2021-2024 | Xeomin |
| Abbott Laboratories | $195.37 | 2020-2024 | Proclaim |
| Scilex Pharmaceuticals INC. | $192.85 | 2019-2024 | |
| Pfizer INC. | $174.96 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $99.37 | 2023-2025 | Horizant, Horizant |
| Averitas Pharma INC. | $93.18 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.89 | 2019-2024 | Relistor |
| Saol Therapeutics INC. | $59.58 | 2020 | |
| Valinor Pharma, LLC | $43.97 | 2023-2024 | Movantik |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynasplint Systems INC. | $39.93 | 2025 | Dynasplint |
| Ibsa Pharma INC. | $39.06 | 2025 | Tirosint, Flector, Licart |
| Virtus Pharmaceuticals LLC | $33.86 | 2023 | Levorphanol Tartrate |
| Daiichi Sankyo INC. | $32.47 | 2019 | |
| Mdd US Operations, LLC | $32.26 | 2019 | |
| Medtronic, INC. | $31.02 | 2021 | |
| Nevro Corp. | $26.03 | 2024 | Senza |
| Assertio Therapeutics, INC. | $24.23 | 2019 | |
| Alfasigma USA, INC. | $19.94 | 2022 | |
| Boston Scientific Corporation | $17.32 | 2023 | |
| Baudax Bio INC. | $17.29 | 2020 | |
| Redhill Biopharma INC. | $16.49 | 2021 | |
| Merz North America, INC. | $16.40 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.81 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.68 | 2020 | |
| Stimwave Technologies Incorporated | $15.57 | 2021 | |
| Amgen INC. | $15.00 | 2019 | |
| Zyla Life Sciences, INC. | $14.80 | 2019 | |
| Nalu Medical, INC. | $14.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.55 | 2022 | |
| Almatica Pharma LLC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyoti Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.